These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 17605004)

  • 1. Modest opioid withdrawal suppression efficacy of oral tramadol in humans.
    Lofwall MR; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2007 Oct; 194(3):381-93. PubMed ID: 17605004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physical dependence potential of daily tramadol dosing in humans.
    Lanier RK; Lofwall MR; Mintzer MZ; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2010 Sep; 211(4):457-66. PubMed ID: 20589494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.
    Lofwall MR; Babalonis S; Nuzzo PA; Siegel A; Campbell C; Walsh SL
    Drug Alcohol Depend; 2013 Nov; 133(1):188-97. PubMed ID: 23755929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.
    Carroll CP; Walsh SL; Bigelow GE; Strain EC; Preston KL
    Exp Clin Psychopharmacol; 2006 May; 14(2):109-20. PubMed ID: 16756415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of repeated tramadol and morphine administration on psychomotor and cognitive performance in opioid-dependent volunteers.
    Mintzer MZ; Lanier RK; Lofwall MR; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2010 Oct; 111(3):265-8. PubMed ID: 20538418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of buprenorphine/naloxone in opioid-dependent humans.
    Stoller KB; Bigelow GE; Walsh SL; Strain EC
    Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans.
    Lofwall MR; Babalonis S; Nuzzo PA; Elayi SC; Walsh SL
    Drug Alcohol Depend; 2016 Jul; 164():143-150. PubMed ID: 27234658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ondansetron Does Not Reduce Withdrawal in Patients With Physical Dependence on Chronic Opioid Therapy.
    Chu LF; Sun J; Clemenson A; Erlendson MJ; Rico T; Cornell E; Obasi H; Sayyid ZN; Encisco EM; Yu J; Gamble JG; Carroll I; Clark JD
    J Addict Med; 2017; 11(5):342-349. PubMed ID: 28514235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.
    Fudala PJ; Yu E; Macfadden W; Boardman C; Chiang CN
    Drug Alcohol Depend; 1998 Mar; 50(1):1-8. PubMed ID: 9589267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent naloxone-induced morphine withdrawal symptoms in opioid-dependent males-a double-blinded, randomized study.
    Weisshaar S; Brandt L; Litschauer B; Sheik-Rezaei S; Moser L; Nirnberger G; Kühberger E; Bauer U; Firbas C; Gouya G; Wolzt M; Fischer G
    Br J Clin Pharmacol; 2020 Aug; 86(8):1610-1619. PubMed ID: 32145041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.
    Mendelson J; Jones RT; Welm S; Baggott M; Fernandez I; Melby AK; Nath RP
    Psychopharmacology (Berl); 1999 Jan; 141(1):37-46. PubMed ID: 9952063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer.
    Sykes NP
    Palliat Med; 1996 Apr; 10(2):135-44. PubMed ID: 8800821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.
    Dunn KE; Weerts EM; Huhn AS; Schroeder JR; Tompkins DA; Bigelow GE; Strain EC
    Addict Biol; 2020 Jan; 25(1):e12680. PubMed ID: 30295400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
    Rehni AK; Bhateja P; Singh TG; Singh N
    Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
    Walsh SL; Strain EC; Bigelow GE
    Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers.
    Lamas X; Farre M; Cami J
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1485-92. PubMed ID: 8138958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
    Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
    Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small-dose naloxone infusion alleviates nausea and sedation without impacting analgesia via intravenous tramadol.
    Jia DL; Ni C; Xu T; Zhang LP; Guo XY
    Chin Med J (Engl); 2010 Jul; 123(13):1695-8. PubMed ID: 20819631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.